The following is a summary of “Longitudinal integrated proteomic and metabolomic skin changes in atopic dermatitis patients ...

Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

Chronic obstructive pulmonary disease (COPD) is a manifestation of structural violence, the process through which societies ...

HealthDay News — In a clinical guideline issued by the American College of Gastroenterology and published in the January issue of the American Journal of Gastroenterology, recommendations are ...

Teaser: Off-label systemic agents may treat inflammatory autoimmune vulvar diseases such as lichen sclerosus and lichen ...

L'Oréal is selling nearly 30 million shares in Sanofi, decreasing its stake in the drugmaker from 9.4% to 7.2%.

Initially developed for atopic dermatitis, Enveda's lead asset ENV-294 is now showing promise in treating asthma.

Dupixent (dupilumab) is tipped to be the market leader among a new generation of inflammation drugs, analysts Evaluate Pharma forecasting it will hit sales of nearly $5 billion by 2022.

Sanofi is already a major player in the ASD market with its big-selling IL-4 and IL-13 inhibitor Dupixent (dupilumab), and the company has previously highlighted amlitelimab as one of a dozen ...

The upcoming report from Regeneron (REGN) is expected to reveal quarterly earnings of $11.60 per share, indicating a decline of 2.2% compared to the year-ago period. Analysts forecast revenues of ...

The Inflation Reduction Act (IRA), passed in 2022, made changes to the way drugs are covered and reimbursed in Medicare.